Additional Pharma Competence proposed for Diamyd Board of Directors

The shareholders of Diamyd Medical AB (publ) are summoned to the Annual General Meeting on Friday December 11, 2009 at 3:00 p.m. at the IVA Conference Center, Grev Turegatan 16 (Wallenberg auditorium) in Stockholm. Under item 11 in the agenda, Diamyd’s Nomination Committee now proposes that an additional Director is elected to the Board of Directors.

The Nomination Committee proposes that Göran Pettersson is elected to Diamyd’s Board of Directors. Göran Pettersson, with degrees in Pharmacy and Marketing, has a long background from leading business functions in the Astra group, KabiVitrum AB, KabiPharmacia/Pharmacia&Upjohn AB and Meda AB. He is currently a Director of the Boards of Medivir AB, OxyPharma AB, Recipharm AB, Swedish Orphan AB and Vivoxid, Oy. ”We welcome Göran as candidate to Diamyd’s Board of Directors. He adds extensive business experience from the pharmaceutical industry and complements the current board in an excellent way,” says Elisabeth Lindner, CEO and President of Diamyd Medical. In accordance with the published agenda, resolutions for items 9-11 are proposed as follows (changes are underlined): Election of Board Members and remuneration etc., items 9-11: The Nomination Committee proposes the re-election of current directors Anders Essen-Möller, Lars Jonsson, Sam Lindgren and Henrik Bonde, and the election of Maria-Teresa Essen-Möller and Göran Petterson. The Committee proposes the re-election of Anders Essen-Möller as Chairman of the Board. The proposed Board Members’ remuneration is SEK 100,000 for each of the Board Members who are not employed at the Company, totaling SEK 500,000. (The Chairman of the Board is a Company employee.) Remuneration includes work on Board committees. It is proposed that the auditors should receive remuneration according to an approved account.

Tags: